Oric Pharmaceuticals Inc (ORIC)
NASDAQ:ORIC
Want to see ORIC full AI Analyst Report?
ORIC Stock Chart & Stats
$10.75
-$0.67(-7.21%)
At close: 4:00 PM EST
$10.75
-$0.67(-7.21%)
Day’s Range― - ―
52-Week Range$7.23 - $14.93
Previous CloseN/A
Volume181.02K
Average Volume (3M)1.64M
Market Cap
$856.09M
Enterprise Value$818.33M
Total Cash (Recent Filing)$281.93M
Total Debt (Recent Filing)$3.30M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 06, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding103,517,560
10 Day Avg. Volume2,154,098
30 Day Avg. Volume1,640,114
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.56K
Enterprise Value/Ebitda-6.11
Forecast
1Y Price Target
$20.20Price Target Upside87.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetMinimal debt and a sizable equity base provide durable financial flexibility to fund R&D and support near-term clinical programs. Low leverage reduces solvency risk versus peers, giving management time to advance registrational studies without imminent debt servicing constraints.
Advancing To Phase 3Selecting a Phase 3 regimen and planning a registrational trial is a structural inflection: it transitions the company from dose-finding to pivotal development, de-risks program timelines if executed, attracts partner interest and clarifies regulatory paths toward potential approval and commercialization.
Clinical Differentiation (efficacy & Safety)Evidence of competitive efficacy plus a differentiated safety profile supports a sustainable competitive advantage if replicated in Phase 3. Better tolerability can expand patient eligibility, drive adoption, and strengthen pricing/coverage dynamics and partner/licensing interest long-term.
Bears Say
No Product RevenueA persistent pre-revenue status means the company's value and sustainability depend entirely on clinical outcomes and external financing. Without product cashflows, ORIC cannot internally fund growth, increasing execution risk and sensitivity to trial timelines and results.
Large, Widening Losses & Negative Cash FlowSignificant and accelerating cash burn with large TTM losses indicates persistent funding needs and potential erosion of equity. Continued negative free cash flow reduces runway, forces more frequent financing, and raises the chance that clinical progress will be interrupted by capital constraints.
Reliance On Capital Raises (dilution Risk)Dependence on equity issuances for operating cash increases dilution risk and can limit strategic flexibility. If market conditions or clinical setbacks impair access to favorable financing, the company may face constrained options or unfavorable terms that hinder long-term program execution.
Oric Pharmaceuticals News
ORIC FAQ
What was Oric Pharmaceuticals Inc’s price range in the past 12 months?
Oric Pharmaceuticals Inc lowest stock price was $7.23 and its highest was $14.93 in the past 12 months.
What is Oric Pharmaceuticals Inc’s market cap?
Oric Pharmaceuticals Inc’s market cap is $856.09M.
When is Oric Pharmaceuticals Inc’s upcoming earnings report date?
Oric Pharmaceuticals Inc’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Oric Pharmaceuticals Inc’s earnings last quarter?
Oric Pharmaceuticals Inc released its earnings results on May 04, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.321 by -$0.019.
Is Oric Pharmaceuticals Inc overvalued?
According to Wall Street analysts Oric Pharmaceuticals Inc’s price is currently Undervalued.
Does Oric Pharmaceuticals Inc pay dividends?
Oric Pharmaceuticals Inc does not currently pay dividends.
What is Oric Pharmaceuticals Inc’s EPS estimate?
Oric Pharmaceuticals Inc’s EPS estimate is -0.36.
How many shares outstanding does Oric Pharmaceuticals Inc have?
Oric Pharmaceuticals Inc has 103,517,560 shares outstanding.
What happened to Oric Pharmaceuticals Inc’s price movement after its last earnings report?
Oric Pharmaceuticals Inc reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.321. Following the earnings report the stock price went down -0.623%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ORIC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oric Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.20 (87.91% Upside)
$20.20 (87.91% Upside)
Blogger Sentiment
Neutral
ORIC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 41.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.47%
12-Months-Change
Fundamentals
Return on Equity
-35.33%
Trailing 12-Months
Asset Growth
79.84%
Trailing 12-Months
Company Description
Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
ORIC Stock 12 Month Forecast
Average Price Target
$20.20
▲(87.91% Upside)
Technical Analysis
Spyre Therapeutics
―
Trevi Therapeutics
―
Praxis Precision Medicines
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
1.05% Insiders
13.74% Mutual Funds
72.23% Other Institutional Investors
1.57% Public Companies and
Individual Investors